A5026393897- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
- Cancer Treatment and Pharmacology
- BRCA gene mutations in cancer
- Estrogen and related hormone effects
- Lung Cancer Research Studies
- Economic and Financial Impacts of Cancer
- Ferroptosis and cancer prognosis
- Cancer-related Molecular Pathways
- Lung Cancer Treatments and Mutations
- Medical Imaging Techniques and Applications
- Prostate Cancer Treatment and Research
- Genetic factors in colorectal cancer
- Cardiac Imaging and Diagnostics
- Radiopharmaceutical Chemistry and Applications
- Neuroendocrine Tumor Research Advances
- Neuroblastoma Research and Treatments
- Epigenetics and DNA Methylation
- Immunotherapy and Immune Responses
- DNA Repair Mechanisms
- Immune cells in cancer
Emory University
2019-2025
Winship Cancer Institute
2022-2024
Emory Healthcare
2024
Piedmont Cancer Institute
2022-2023
Northwestern University
2010-2020
University of Michigan
2017
Nonalcoholic steatohepatitis (NASH) is an independent predictor of coronary artery disease (CAD). Our aim was to compare the incidence cardiovascular (CV) events between patients transplanted for NASH and alcohol (ETOH)-induced cirrhosis. This a retrospective cohort study (August 1993 March 2010) 242 (115 127 ETOH) with ≥12 months follow-up after liver transplantation (LT). Those hepatocellular carcinoma or coexisting diseases were excluded. Kaplan-Meier's Cox's proportional hazard analyses...
HER2 mutations are targetable alterations in patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC). In the SUMMIT basket study, HER2-mutant MBC received neratinib monotherapy, + fulvestrant, or fulvestrant trastuzumab (N F T). We report results from 71 HR+, MBC, including 21 (seven each arm) a randomized substudy of versus (F T) N T.
663 Background: Dato-DXd is a TROP2-directed antibody-drug conjugate under investigation in various solid tumor types. We report updated results patients (pts) with locally advanced/metastatic urothelial cancer (la/m UC) from the ongoing phase 1 TROPION-PanTumor01 study (NCT03401385). Methods: Pts unresectable la/m UC (stage III/IV) treated ≥1 prior line of therapy, including an immune checkpoint inhibitor, received 6 mg/kg Q3W. Primary objectives were safety and tolerability. Secondary...
1021 Background: Imlunestrant is a novel, orally bioavailable SERD with pure antagonistic properties that result in sustained inhibition of ER-dependent gene transcription and cell growth. In dose escalation, imlunestrant showed favorable safety, pharmacokinetics (PK) preliminary efficacy patients ER+, HER2- aBC ER+ EEC (Phase 1a EMBER, Jhaveri 2021). Here we present updated data from the escalation 1a) expansion 1b) monotherapy EMBER (NCT04188548). Methods: Phase 1a/1b enrolled (prior ET...
The Immunoscore is a method to quantify the immune cell infiltration within cancers predict disease prognosis. Previous profiling approaches relied on limited markers establish patients' tumor immunity. However, cells exhibit higher-level complexity that typically not obtained by conventional immunohistochemistry methods. Herein, we present spatially variant score, termed as SpatialVizScore, lung samples using multiplex protein imaging data. Imaging mass cytometry (IMC) was used target 26 in...
603 Background: Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate consisting of a humanized anti-TROP2 IgG1 monoclonal antibody covalently linked to highly potent topoisomerase I inhibitor payload via plasma-stable, tumor-selective, tetrapeptide-based cleavable linker. Dato-DXd has shown encouraging antitumor activity and manageable safety profile in patients (pts) with solid tumors. We report preliminary results pts advanced/metastatic (a/m) urothelial cancer from the ongoing...
Abstract Background: ctDNA monitoring during adjuvant endocrine therapy provides an opportunity to detect molecular relapse before clinically apparent recurrence. The rate and dynamics of positivity the frequency asymptomatic but imaging detectable metastatic disease at time detection remain unknown in high-risk ER+/HER2- breast cancers. We present results rates 508 ctDNA+ patients from a prospective, multicenter, randomized surveillance intervention trial, DARE (NCT04567420). Patients...
Anaplastic lymphoma kinase (ALK) inhibitors are the mainstay treatment for patients with non-small cell lung carcinoma (NSCLC) harboring a rearrangement of ALK gene or ROS1 oncogenes. With recent publication pivotal trials leading to approval these compounds in different indications, their toxicity profile warrants an update.A systematic literature search was performed July 2017. Studies evaluating US FDA approved doses one following inhibitors: Crizotinib, Ceritinib, Alectinib Brigatinib as...
Abstract Background The treatment landscape for HR(+)HER2(−) metastatic breast cancer (MBC) is evolving patients with ESR1 mutations (mut) and PI3K/AKT pathway genomic alterations (GA). We sought to inform clinical utility comprehensive profiling (CGP) using tissue (TBx) liquid biopsies (LBx) in MBC. Methods Records from a de-identified clinicogenomic database who underwent TBx/LBx testing at Foundation Medicine during routine care ~ 280 US clinics between 01/2011 09/2023 were assessed. GA...
A 62-year-old woman with right-sided invasive lobular breast carcinoma completed external beam radiotherapy 6 weeks before undergoing a 68 Ga-PSMA PET/CT and 18 F-fluciclovine scan as part of an ongoing clinical trial (NCT04750473) assessing the performance these molecular imaging modalities in carcinoma. The demonstrated band-like area increased radiotracer uptake dome right lobe liver anteriorly, whereas done day later revealed photopenia corresponding liver. plan confirmed that field...
VeriStrat test is a serum assay which uses mass spectrometry (MS)-based proteomic signature derived from machine learning. It currently used as prognostic marker for patients with non-small cell lung cancer (NSCLC) receiving chemotherapy. However, little known about its role NSCLC immune checkpoint inhibitors (ICIs).This retrospective study that includes 47 advanced stage without an activating EGFR mutation, who underwent the 2016 to 2018. Spectra blood samples were evaluated assign into...
Abstract Background: Imlunestrant is an oral, brain-penetrant selective estrogen receptor degrader, designed to deliver continuous ER target inhibition, including in ESR1-mutant breast cancer. In the first-in-human dose escalation/expansion (Phase 1a/1b) study of EMBER trial (NCT04188548), imlunestrant showed favorable safety, pharmacokinetics, and clinical benefit pre-treated patients with ER+, HER2- aBC when administered as monotherapy (Jhaveri, ASCO 2022) or abemaciclib ± aromatase...
2583 Background: Systemic activation of multiple immune receptors, such as Toll-like Receptor (TLR), Nucleotide oligomerization domain (NOD) like, and Stimulator interferon genes (STING) may be required for efficient anti-tumor responses. Decoy20 is an attenuated, killed, non-pathogenic, bacterial product with ~90% reduction lipopolysaccharide (LPS)-endotoxin activity to enhance intravenous (IV) safety, retention endogenous TLR1/2,2/6,8,9, NOD2 STING agonist activity. produced pre-clinical...
Abstract Background: Imlunestrant is a novel, orally bioavailable selective estrogen receptor degrader (SERD) with pure antagonistic properties that result in sustained inhibition of (ER)-dependent gene transcription and cell growth. In phase 1 study, imlunestrant monotherapy showed favourable safety, pharmacokinetics (PK) preliminary efficacy heavily pre-treated ER-positive (ER+) advanced breast cancer patients (Jhaveri ASCO 2022). Here, we present pharmacodynamic (PD) data from the...
Abstract Background: Aberrant PI3K pathway signaling is frequently observed in TNBC. Increasing evidence indicate that activation maintains the stemness and chemoresistance of breast cancer stem cells (CSCs). inhibition sensitizes CSCs to chemotherapy. Eribulin (E), a non-taxane microtubule dynamics inhibitor, showed overall survival benefit metastatic HER2 negative BC. Preclinically, addition copanlisib (C), potent pan-class I inhibitor highly selective against α δ isoforms, improved...